Table 1.
Subject characteristics
| Clinical Characteristic | Control | UF | Total | P |
|---|---|---|---|---|
| n | 39 (35%) | 74 (65%) | 113 (100%) | |
| Age (years) | 55.5 ± 11.5 | 54.3 ± 12.6 | 54.7 ± 12.2 | 0.6 |
| Male | 31 (79%) | 48 (65%) | 79 (70%) | 0.1 |
| Race | 0.8 | |||
| white | 3 (8%) | 9 (12%) | 12 (11%) | |
| black | 35 (90%) | 63 (85%) | 98 (87%) | |
| other | 1 (3%) | 2 (3%) | 3 (3%) | |
| Pre-HD seated BP | 157.8 ± 15.8/87.0 ± 12.8 | 158.5 ± 16.2/85.5 ± 10.5 | 158.3 ± 16.0/86.0 ± 11.3 | 0.8/0.5 |
| Post-HD seated SBP | 141.5 ± 19.9/77.1 ± 13.2 | 142.9 ± 17.6/78.0 ± 10.1 | 142.4 ± 18.3/77.7 ± 11.2 | 0.7/0.7 |
| Pre-HD weight (kg) | 82.8 ± 16.7 | 82.2 ± 20.0 | 82.4 ± 18.8 | 0.9 |
| Post-HD weight (kg) | 80.0 ± 16.1 | 79.2 ± 19.2 | 79.5 ± 18.1 | 0.8 |
| Body mass index (kg/m2) | 26.7 ± 5.9 | 26.8 ± 5.7 | 26.7 ± 5.7 | 0.9 |
| Years on dialysis | 4.3 ± 6.0 | 3.6 ± 4.2 | 3.9 ± 4.9 | 0.5 |
| Etiology of ESRD | 0.7 | |||
| diabetes mellitus | 15 (38%) | 31 (42%) | 46 (41%) | |
| hypertension | 18 (46%) | 31 (42%) | 49 (43%) | |
| glomerulonephritis | 2 (5%) | 3 (4%) | 5 (4%) | |
| polycystic kidney disease | 0 (0%) | 3 (4%) | 3 (3%) | |
| other | 4 (10%) | 6 (8%) | 10 (9%) | |
| Current smoker | 15 (38%) | 23 (31%) | 38 (34%) | 0.4 |
| History of | ||||
| congestive heart failure | 4 (10%) | 15 (20%) | 19 (17%) | 0.2 |
| myocardial infarction | 6 (15%) | 13 (18%) | 19 (17%) | 0.8 |
| stroke | 4 (10%) | 7 (9%) | 11 (10%) | 0.9 |
| Urea reduction ratio (%) | 73.0 ± 6.3 | 74.2 ± 7.4 | 73.8 ± 7.0 | 0.4 |
| Albumin (g/dl) | 3.8 ± 0.4 | 3.7 ± 0.5 | 3.7 ± 0.5 | 0.9 |
| Hemoglobin (g/dl) | 12.1 ± 1.4 | 12.2 ± 1.1 | 12.2 ± 1.2 | 0.7 |
| Presence of pedal edema | 7 (18%) | 16 (22%) | 23 (20%) | 0.6 |
| Number receiving anti-hypertensive drugs | 29 (74%) | 63 (85%) | 92 (81%) | 0.2 |
| Number of anti-hypertensives in users | 2.1 ± 1.7 | 2.2 ± 1.6 | 2.1 ± 1.6 | 0.8 |
| Dihydropyridine calcium channel blockers | 16 (41%) | 33 (45%) | 49 (43%) | 0.7 |
| Non-dihydropyridine calcium channel blockers | 2 (5%) | 4 (5%) | 6 (5%) | 0.9 |
| β-blockers | 25 (64%) | 50 (68%) | 75 (66%) | 0.7 |
| α-blockers | 3 (8%) | 5 (7%) | 8 (7%) | 0.9 |
| Centrally acting agents | 8 (21%) | 21 (28%) | 29 (26%) | 0.4 |
| Vasodilators | 9 (23%) | 10 (14%) | 19 (17%) | 0.2 |
| ACE inhibitors | 20 (51%) | 38 (51%) | 58 (51%) | 1 |
| Angiotension receptor blockers | 4 (10%) | 14 (19%) | 18 (16%) | 0.2 |